TENK
TenX Keane Acquisition

401
Mkt Cap
$77.5M
Volume
167,011.00
52W High
$6.19
52W Low
$0.4912
PE Ratio
-3.00
TENK Fundamentals
Price
$0.924
Prev Close
$0.8779
Open
$0.91
50D MA
$0.8859
Beta
-2.20
Avg. Volume
435,238.11
EPS (Annual)
-$0.338
P/B
1.34
$148.61
Loading...
Loading...

About

Citius Oncology, Inc. is a biopharmaceutical company, which engages in developing and commercializing targeted oncology therapies. Its lead product candidate is LYMPHIR, an engineered IL-2 diphtheria toxin fusion protein, for the treatment of patients with persistent or recurrent CTCL, a rare form of non-Hodgkin lymphoma. The company was founded on March 1, 2021 and is headquartered in Cranford, NJ.
Sector:
Health Technology
Industry:
Pharmaceuticals Major
Employees:
N/A

Frequently Asked Questions

What is Market Cap of Citius Oncology Inc.?
What is the 52-week high for Citius Oncology Inc.?
What is the 52-week low for Citius Oncology Inc.?
What is Citius Oncology Inc. stock price today?
What was Citius Oncology Inc. stock price yesterday?
What is the PE ratio of Citius Oncology Inc.?
What is the Price-to-Book ratio of Citius Oncology Inc.?
What is the 50-day moving average of Citius Oncology Inc.?

Latest TENK News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.